Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05607719 | Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD | PHASE2 | ACTIVE NOT_RECRUITING | 30 | — | — | Apr 11, 2023 | Jun 30, 2026 | Apr 23, 2026 | 1 | United States |
Echocardiographic assessment of PVR before and after inhalation of 180 μg albuterol as a test of endothelial function
| Arm | Type | Description |
|---|---|---|
| Bretzri followed by Bevespi Group | EXPERIMENTAL | Participants in this group will receive Bretzri for 4-weeks followed by 8-weeks of Bevespi. |
| Bevespi followed by Bretzri Group | EXPERIMENTAL | Participants in this group will receive Bevespi for 8-weeks followed by 4-weeks of Bretzri. |
| Name | Type | Description |
|---|---|---|
| Bevespi | DRUG | Two puffs twice a day |
| Bretzri | DRUG | Two puffs twice a day |
Inclusion Criteria: * physician diagnosis of COPD * former smoking history of more than 10 pack-years * baseline post-bronchodilator one-second forced expiratory volume (FEV1) 50-80% of predicted, baseline FEV1 and forced vital capacity (FVC) ratio \<0.7 * males and females, 40-80 years of age * re...